Floatz logo

Tivantinib

Clear Cell Sarcoma (CCS)

ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)Small moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

11 Active assets in the Clear Cell Sarcoma (CCS) cohort.

Asset / SponsorPhaseRating
Crizotinib
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2B
Atezolizumab
National Cancer Institute (NCI)
Phase 2CCC
Cobimetinib
Radboud University Medical Center
Phase 2CCC
Bms-907351
National Cancer Institute (NCI)
Phase 2CCC
VEMURAFENIB
Radboud University Medical Center
Phase 2CCC

View all 19 →

Same molecule, other indications

Tivantinib is also rated in:

non-small cell lung carcinomaDormant
BB
Indicative ·
68 / 100
View asset →
renal cell carcinomaDormant
B
Indicative ·
62 / 100
View asset →
hepatocellular carcinomaDormant
B
Indicative ·
61 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →